Please select the option that best describes you:
In which patients with non-proteinuric chronic kidney disease would you initiate a SGLT2i?
Answer from: at Community Practice
I agree with Dr. Wish. I do not use SGLT2i in non-proteinuric diseases for kidney protection indication. EMPA-Kidney study also did not show benefit for UACR <30 (HR 1.01, 0.66-1.55) among >1200 participants with UACR <30 in the trial. While the secondary analysis looking at mean annual cha...
Sign in or Register to read more
Answer from: at Community Practice
At this point, the answer is none, since I wouldn't have decrease in proteinuria as a marker to assess the efficacy of the SGLT2i. Also, since the use of SGLT2i's in non-proteinuric CKD is off-label, I doubt any prescription drug plan would approve payment for these agents in such a setting (other t...
Comments
at Renal And Transplant Associates Of New England Pc
Putting aside the benefits of SGLT2i in HFrEF and ...
Putting aside the benefits of SGLT2i in HFrEF and ...
Answer from: at Academic Institution
At this time, I don't. I think we need more data before starting SGLT2i for kidney disease in non-proteinuric patients. Of course, they may be on one because of heart disease or diabetes by other physician. In that case, I clearly would not stop them.